Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions

Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions

Tamoxifen is used in the treatment of women with endocrine responsive breast cancer. It is a prodrug, which is metabolized by liver cytochrome P450 system (CYP) into metabolites with a potent anti-estrogenic activity; CYP2D6 is one of the most important enzymes involved in this metabolic pathway. Lo...

Full description

Saved in:
Bibliographic Details
Published in:Zdravniški vestnik (Ljubljana, Slovenia : 1992) Vol. 81; no. 7-8
Main Authors: Boštjan Šeruga, Brigita Novak Šarotar, Lea Knez, Simona Borštnar, Rado Janša, Marga Kocmur, Tanja Čufer
Format: Journal Article
Language:English
Published: Slovenian Medical Association 01-08-2012
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tamoxifen is used in the treatment of women with endocrine responsive breast cancer. It is a prodrug, which is metabolized by liver cytochrome P450 system (CYP) into metabolites with a potent anti-estrogenic activity; CYP2D6 is one of the most important enzymes involved in this metabolic pathway. Low or absent activity of CYP2D6, which can be inherited and/or can occur due to the use of CYP2D6 inhibitors, may impair outcome in women with tamoxifentreated breast cancer. Antidepressants, which can also inhibit CYP2D6, are among the most commonly prescribed drugs in women with breast cancer. Breast cancer patients receiving tamoxifen should not be co-prescribed antidepressants or any other drugs, which are potent inhibitors of CYP2D6.
ISSN:1318-0347
1581-0224